



Value Life

Vygon Group invests over €7 million (\$8m) opening its 10th plant

Located in Portugal, the facility will mainly produce the Qimono range of extra-safe connectors used in chemotherapy

Ecouen, France, March 29, 2016 – Vygon, the specialist single-use medical devices group, today announces that operations started at its new production facility in Paredes, northeast of Porto, Portugal. Extensive building work took place between January and November 2015 at a total cost of €7m (\$8m). The plant has been operational since the end of 2015. Covering an area of 25,000 m², the site will be used primarily to produce Vygon's Qimono range of innovative medical devices for use in oncology. The company plans to create more than 120 jobs in the area over the next five years.

Vygon Group now has 10 plants: four in France and one each in Belgium, Germany, Portugal, the US, Columbia and Mauritius. The company produces 85% of its ranges in Europe. These account for 89% of the value of its products.

The Paredes plant is a pilot facility that will allow Vygon to move its new products from the design to the production stage. The main focus will be on producing Qimono, a comprehensive range of extra-safe connectors that can be used at all stages of the chemotherapy process. The validation program for the product range started towards the end of 2015 and the site successfully packaged the first batches of products before the start of 2016. If required, the plant can double its production capabilities and increase its storage facilities by a further 50%. In due course, it is also expected to handle the launch of new product ranges. Depending on the market for these ranges, the Group may then decide to automate large-scale production at its other historical manufacturing sites.

"This new facility forms an integral part of our Vygview 2022 vision and our industrial infrastructure, with the aim of improving our responsiveness between the product design and the automated production phases," said Stéphane Regnault, chairman of Vygon's management board. "The new plant has an important role to play in Vygon Group's growth. It will improve our ability to meet our customers' needs. The Qimono range taps into a fast-growing market that will help drive the Group's organic growth over the next few years."

Director of Vygon Portugal, José Martins, added: "This multi-million euro investment in Europe will provide Vygon with a cutting-edge production facility, close to our key markets and our customers, in a region with readily available qualified personnel."



Value Life

About Vygon

Vygon designs, manufactures and markets high-tech single-use medical devices for health care professionals in hospital and for private and independent practitioners.

Vygon is a world leader within this industry, offering a wide range of products in a number of clinical specialties: neonatology, adult and pediatric critical care, anesthesia, long-term vascular access, oncology, emergency, cardiovascular and surgery, and home care.

With expertise right along the value chain, from product design to the delivery of training for medical personnel, Vygon provides health care professionals with effective and innovative products tailored to their needs and those of their patients, for optimum use and safety.

The company distributes over 205 million products a year in more than 120 countries through its network of 27 subsidiaries and 331 distributors. Vygon products display the CE and/or FDA mark and are manufactured in the group's eight factories in Europe, the USA and Colombia.

A family company founded in 1962, Vygon is based in Ecouen, in France's Greater Paris region. It is a mid-sized business employing 2,150 staff worldwide. The turnover in 2015 was €302 million (\$328.6 million), with 81% of this derived from Vygon's international business.

www.vygon.com

Media contacts and analysts

Andrew Lloyd & Associates [@ALA_Group](#)

Lise Beltzung / Juliette dos Santos

lise@ala.com / juliette@ala.com

Tel: +44 1273 675 100

US + 1 617 202 4491